197 related articles for article (PubMed ID: 21410764)
21. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
22. Tyrosinase and nestin immunohistochemical expression in melanocytic nevi as a histopathologic pattern to trace melanocyte differentiation and nevogenesis.
Murtas D; Pilloni L; Diana A; Casula L; Tomei S; Piras F; Ferreli C; Maxia C; Perra MT
Histochem Cell Biol; 2019 Feb; 151(2):175-185. PubMed ID: 30232588
[TBL] [Abstract][Full Text] [Related]
23. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
24. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
Seleit IA; Samaka RM; Basha MA; Bakry OA
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
[TBL] [Abstract][Full Text] [Related]
25. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
26. Expression of embryonic stem cell markers SOX2 and nestin in dermatofibrosarcoma protuberans and dermatofibroma.
Sellheyer K; Nelson P; Patel RM
J Cutan Pathol; 2011 May; 38(5):415-9. PubMed ID: 21251041
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma.
Akiyama M; Matsuda Y; Ishiwata T; Naito Z; Kawana S
J Invest Dermatol; 2013 May; 133(5):1384-7. PubMed ID: 23389394
[No Abstract] [Full Text] [Related]
29. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
30. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
[TBL] [Abstract][Full Text] [Related]
31. The stem cell marker nestin predicts poor prognosis in human melanoma.
Piras F; Perra MT; Murtas D; Minerba L; Floris C; Maxia C; Demurtas P; Ugalde J; Ribatti D; Sirigu P
Oncol Rep; 2010 Jan; 23(1):17-24. PubMed ID: 19956860
[TBL] [Abstract][Full Text] [Related]
32. Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease.
Sharma BK; Manglik V; Elias EG
J Surg Res; 2010 Sep; 163(1):e11-5. PubMed ID: 20638684
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
34. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
35. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
36. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
37. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
38. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential.
Wu H; Barusevicius A; Babb J; Klein-Szanto A; Godwin A; Elenitsas R; Gelfand JM; Lessin S; Seykora JT
J Cutan Pathol; 2005 Feb; 32(2):125-30. PubMed ID: 15606670
[TBL] [Abstract][Full Text] [Related]
39. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
40. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.
Thomas-Pfaab M; Annereau JP; Munsch C; Guilbaud N; Garrido I; Paul C; Brousset P; Lamant L; Meyer N
J Dermatol Sci; 2013 Feb; 69(2):105-13. PubMed ID: 23219141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
